Alpha 2.0
Login Register
» Articles » PMID: 33596004

Impact of COVID- 19 Infection Among Hospitalized Amyotrophic Lateral Sclerosis Patients

Overview
Journal J Clin Neuromuscul Dis
Specialties Neurology
Physiology
Date 2021 Feb 17
PMID 33596004
Citations 5
Authors
Lakshmi P Digala
Shivika Prasanna
Praveen Rao
Raghav Govindarajan
Adnan I Qureshi
Affiliations
Soon will be listed here.
Citing Articles

Impact of SARS-CoV-2 infection and COVID-19 pandemic on the morbidity and mortality of amyotrophic lateral sclerosis patients in Valencia, Spain.

Garcia-Casanova P, Perez-Martinez P, Sevilla T, Domenech R, Leon M, Vazquez-Costa J Eur J Neurol. 2024; 31(12):e16465.

PMID: 39240038 PMC: 11554849. DOI: 10.1111/ene.16465.

A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.

Lombardo F, Spila Alegiani S, Mayer F, Cipriani M, Lo Giudice M, Ludolph A Trials. 2023; 24(1):792.

PMID: 38053196 PMC: 10696667. DOI: 10.1186/s13063-023-07638-w.

Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids.

Meacci E, Pierucci F, Garcia-Gil M Biomedicines. 2022; 10(5).

PMID: 35625805 PMC: 9138286. DOI: 10.3390/biomedicines10051068.

Covid-19 threat and coping: application of protection motivation theory to the pandemic experiences of people affected by amyotrophic lateral sclerosis.

Genuis S, Luth W, Bubela T, Johnston W BMC Neurol. 2022; 22(1):140.

PMID: 35413805 PMC: 9002218. DOI: 10.1186/s12883-022-02662-w.

Accelerated Early Progression of Amyotrophic Lateral Sclerosis over the COVID-19 Pandemic.

De Marchi F, Gallo C, Sarnelli M, De Marchi I, Saraceno M, Cantello R Brain Sci. 2021; 11(10).

PMID: 34679356 PMC: 8534200. DOI: 10.3390/brainsci11101291.